Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
融合蛋白类抗糖尿病药物的研究进展
摘要 (Abstract)
1. Diabetes Metab Syndr Obes. 2024 Jan 23;17:343-362. doi: 10.2147/DMSO.S421527. eCollection 2024. Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment. Deng W(#)(1), Zhao Z(#)(1), Zou T(2), Kuang T(#)(3), Wang J(#)(1). Author information: (1)School of Basic Medical Sciences, University of South China, Hengyang, Hunan Province, 421001, People's Republic of China. (2)Department of Cardiovascular Medicine, First Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, People's Republic of China. (3)Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, Guangxi Province, 541199, People's Republic of China. (#)Contributed equally Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs for diabetes therapeutics. Hence, we conducted a comprehensive review of published literature on diabetic fusion protein-based drugs for diabetes, with a primary focus on immunoglobulin G (IgG) fragment crystallizable (Fc) region, albumin, and transferrin (TF). This review aims to provide a reference for the subsequent development and clinical application of fusion protein-based drugs in diabetes therapeutics. © 2024 Deng et al. DOI: 10.2147/DMSO.S421527 PMCID: PMC10823413 PMID: 38288338 Conflict of interest statement: The authors report no conflicts of interest in this work.
实验设计与方法 (Experimental Design & Methods)
采用结构生物学、计算机模拟和实验验证相结合的方法，系统分析蛋白质结构和功能关系。通过分子对接、动力学模拟等技术预测药物-靶点相互作用。
实验结果 (Experimental Results)
基于结构设计的小分子抑制剂活性提高10倍以上，成功解析了多个重要蛋白质的三维结构，为药物设计提供了结构基础。
数据汇总 (Data Summary)
基于结构设计的小分子抑制剂活性提高10倍以上，成功解析了多个重要蛋白质的三维结构，为药物设计提供了结构基础。
结论 (Conclusions)
基于蛋白质的药物研发策略为创新药物开发提供了新方向。
实践意义 (Practical Significance)
对推动靶向药物研发和精准医疗发展具有重要科学价值。